Immunovia

86 articles with Immunovia

• Immunovia to Host a Second Webinar in the Series on IMMray™ PanCan-d: Commercial Test Model Study & Update on Launch Activities

  8/18/2020

  Immunovia AB, announced that the company will be hosting the second webinar in the series on Immunovia's IMMray™ PanCan-d.

• Invitation to presentation of Immunovia's interim report January - June 2020 on August 20, 2020

  8/13/2020

  Immunovia invites to a teleconference for investors, analysts and media on Thursday, August 20th, 2020 at 16:30 CET.

• Change in the Number of Shares and Votes in Immunovia AB (publ)

  6/30/2020

  Immunovia AB announced that the number of shares and votes in Immunovia has changed due to the fact that shares have been registered after the directed share issue which was carried out in June 2020.

• Immunovia Targeting Long-Term Market Penetration of 30% for IMMray™ PanCan-d

  6/30/2020

  Immunovia AB announced the company's long-term market penetration target of 30% for IMMray™ PanCan-d, after reimbursement and widespread insurance coverage is achieved.

• Immunovia to Present a Satellite Symposium at the European Pancreatic Club (EPC) - International Association of Pancreatology's (IAP) Annual Meeting July 2, 2020

  6/29/2020

  Immunovia AB (publ) ("Immunovia") today announced the company will be presenting at the 52 nd EPC-IAP annual meeting on July 2 , 2020.  This year's event will be held virtually and will be the place to watch and listen to great lectures and latest research in Pancreatology.  The registration for this year's event is open and can be ma

• Immunovia Expands its Lung Cancer Program Based on Encouraging Results From the Current Discovery Study

  6/26/2020

  Immunovia AB announced that the results of the current study in lung cancer strongly supports an expansion into the next stage in the discovery process.

• Registration Details for Immunovia's Virtual Investor Day on Tuesday, June 30, 2020

  6/26/2020

   Immunovia AB (publ) ("Immunovia") today announced the registration details for the company's Virtual Investor Day on Tuesday, June 30, 2020 , from 2:00 to 4:00 pm CET .  The online event will feature presentations by Immunovia's Chairman, Carl Borrebaeck ; CEO, Mats Grahn ; Chief Commercial Officer, Laura Chirica ; Senior VP

• Immunovia to Host Virtual Investor Day on Tuesday, June 30, 2020

  6/15/2020

  Immunovia AB (publ) ("Immunovia") today announced the company will host a Virtual Investor Day on Tuesday, June 30, 2020 , from 2:00 to 4:00 pm CET .  The online event will feature presentations by Immunovia's Chairman, Carl Borrebaeck ; CEO, Mats Grahn ; Chief Commercial Officer, Laura Chirica ; Senior VP Sales North America,

• Immunovia Raised ~ 400m SEK to Further Accelerate the Market Introduction of the First Test for Early Detection of Pancreatic Cancer, the IMMray™ PanCan-d

  6/9/2020

  On June 4 th , Immunovia announced a Directed Share Issue raising ~400 MSEK in capital, resulting in one of the largest fundraising for a non-US based diagnostics company. Proceeds from this Directed Share Issue will be used for the commercialization activities associated with the launch of IMMray ™ PanCan-d. These activities include

• Immunovia Provides Forth Update During COVID-19 Pandemic

  5/27/2020

  Immunovia AB (publ) ("Immunovia") today provides an update on the actions that the company is taking in response to the coronavirus (COVID-19) pandemic. During these challenging times, Immunovia remains focused on the sales start of the first-to-market test for early diagnosis of pancreatic cancer, IMMray™ PanCan-d.

• Invitation to Immunovia's Update #4 on COVID-19 Company Response

  5/26/2020

  Immunovia invites you to a teleconference for all stakeholders and media on Wednesday, May 27, 2020 at 16:30 CET.

• Immunovia Provides Third Update During COVID-19 Pandemic

  5/13/2020

  Immunovia AB (publ) ("Immunovia") today provides an update on the actions that the company is taking in response to the coronavirus (COVID-19) pandemic. During these challenging times, Immunovia remains focused on the sales start of the fi

• Invitation to Immunovia's Update #3 on COVID-19 Company Response

  5/12/2020

  Immunovia invites you to a teleconference for all stakeholders and media on Wednesday, May 13, 2020 at 16:30 CET.

• Immunovia - Report From AGM - May 08, 2020

  5/8/2020

  The Annual General Meeting of Immunovia AB, corporate identity number 556730-4299 was held in The Spark at Medicon Village, Scheeletorget 1, Lund on May 7, 2020.

• 

  BioSpace Global Roundup, April 30

  4/30/2020

  Biopharma companies from across the globe provide updates on their business and pipelines.

• Immunovia Reports First Quarter Interim Report January - March 2020

  4/28/2020

    [28-April-2020]   LUND, Sweden , April 28, 2020 /PRNewswire/ --   Immunovia has today published first quarter interim report for January - March 2020 . It is available on Immunovia's website . "During Q1 2020, Immunovia worked hard and continued to make great strides towards IMMray™ PanCan-d's launch and the sales start of the first test for early diagnosis of pancreatic cancer, in spite of

• Invitation to Presentation of Immunovia's Interim Report January - March 2020 on April 28, 2020

  4/22/2020

  Immunovia invites to a teleconference for investors, analysts and media on Tuesday, April 28th, 2020 at 16:30 CET.

• Immunovia and Global Pharmaceutical Company Agree on Early Termination of Lung Cancer Collaboration

  4/8/2020

  Immunovia AB announced that the company's Lung Cancer collaboration with a global pharmaceutical company has been terminated.

• Immunovia Takes Action During COVID-19 Pandemic and Remains Focused on Launch of IMMray™ PanCan-d

  4/1/2020

  Immunovia AB  (publ) ("Immunovia") today provides an update on the actions that the company is taking to support patients, employees, and public health initiatives in response to the coronavirus (COVID-19) pandemic. Despite these extraordinary times, Immunovia remains focused on the Q3 2020 sales start for the first test for early dia

• Invitation to a Company Update on the COVID-19 Response

  3/30/2020

  Immunovia invites you to a teleconference for all stakeholders and media on Wednesday, April 1, 2020 at 16:30 CET.